How Does IVIg Wear Off in Multifocal Motor Neuropathy?

Some people with Multifocal Motor Neuropathy (MMN) notice that their weakness returns in the days just before their next Intravenous Immunoglobulin (IVIg) infusion. This is a recognized pattern commonly called the wearing-off effect or end-of-dose effect.

While this phenomenon is well-documented, new, rapidly worsening, or severe weakness should never automatically be assumed to be a normal wearing-off effect. It is important to work with your neurology team to determine if these symptom fluctuations are tied to your infusion schedule, or if they reflect disease progression or another medical issue ^[1].

Why Does the Wearing-Off Effect Happen?

In MMN, the immune system mistakenly attacks the motor nerves, specifically targeting areas called the nodes of Ranvier. This attack causes “conduction block,” meaning the electrical signals telling your muscles to move are temporarily interrupted. In some (but not all) patients, this is associated with specific markers called anti-GM1 antibodies ^[2].

IVIg treats this by introducing pooled human IgG (immunoglobulin) from thousands of healthy donors into your bloodstream. The exact way IVIg works in MMN is complex and not fully understood, but it helps quiet the immune response and restore nerve signaling ^[2].

However, your body naturally breaks down and clears these donor antibodies over a period of weeks ^[3]. Your IgG levels reach a peak shortly after your infusion and slowly drop to their lowest point (the trough level) right before your next scheduled dose. Researchers propose that when these trough levels drop, the protective immunomodulatory effect may weaken, allowing nerve inflammation and weakness to temporarily return ^[3].

Distinguishing “Wearing Off” From Disease Progression

Not all returning weakness is an end-of-dose fluctuation. It is important to distinguish temporary wearing-off from long-term disease progression, though both can sometimes happen at the same time:

• The Wearing-Off Pattern: This is a predictable, repeating cycle. Weakness noticeably increases in the days just before an infusion, and improves again after the infusion is complete. Keep in mind that improvement may take days or longer to become apparent, and some individuals do not experience a clear peak-and-trough pattern.
• Axonal Degeneration: Over time, ongoing immune attacks in MMN can cause permanent nerve damage, known as secondary axonal degeneration. Weakness caused by this type of damage tends to be fixed and will not improve even after an IVIg infusion ^[1].

Because subjective feelings of fatigue can sometimes mimic true muscle weakness, your doctor may suggest keeping a symptom log. Documenting exactly when your symptoms begin, which specific functions change, and when you recover can help your doctor see the underlying pattern. In some cases, clinicians may recommend tracking your grip strength at home with a hand dynamometer ^[4]. If you do this, you must use the same device, technique, hand position, and time of day for each measurement. Remember that grip strength alone cannot capture weakness in your legs or other muscle groups, and it does not replace a formal neurological exam.

How Your Care Team Can Manage the Wearing-Off Effect

If you are experiencing a confirmed wearing-off pattern, tell your treatment team. There are several clinician-supervised options that may be considered, as IVIg schedules are highly individualized ^[5]. Never attempt to change your dose or delay your infusion without your neurologist’s explicit instruction.

• Shortening the Infusion Interval: Instead of receiving infusions every 4 weeks, your doctor might suggest a shorter interval, such as every 2 or 3 weeks. Pharmacokinetic modeling and small clinical studies suggest that giving infusions more frequently may keep the amount of IgG in your blood steadier, potentially leading to more consistent strength and fewer symptom fluctuations ^[3][6].
• Increasing the Dose: In some cases, your doctor may cautiously increase your total monthly IVIg dose in an effort to keep your trough levels higher at the very end of your cycle ^[5][6].
• Subcutaneous Immunoglobulin (SCIg): SCIg is an alternative form of immunoglobulin therapy that you administer yourself at home, usually weekly or multiple times per week. Because the doses are smaller and given much more frequently, SCIg provides more stable antibody levels in the blood ^[7]. However, evidence for SCIg in MMN comes mostly from small studies, and it may be considered an “off-label” use depending on your country and the specific product. Transitioning to SCIg requires practical training, often causes local injection-site skin reactions ^[8], and some patients may require an overall dose increase to maintain their strength ^[9].

Safety and When to Seek Urgent Help

All immunoglobulin therapies carry risks. IVIg can cause immediate infusion reactions like headache, fever, and nausea ^[10]. More rarely, it can cause severe delayed complications such as blood clots (thromboembolism), acute kidney injury, aseptic meningitis, or severe allergic reactions (anaphylaxis) ^[11]. Changing your dose or administration method requires your doctor to carefully weigh these risks against the potential benefits.

Seek immediate, emergency medical care if you experience:

• Sudden or rapidly worsening weakness that is completely outside your usual wearing-off pattern.
• New difficulty breathing, swallowing, or speaking.
• Chest pain, shortness of breath, or sudden swelling in a limb (potential signs of a blood clot).
• Signs of a severe allergic reaction during or after an infusion.